Health CarePharmaceuticals & Biotechnology
  • Price (USD)215.13
  • Today's Change0.13 / 0.06%
  • Shares traded978.35k
  • 1 Year change34.66%
  • Beta1.4712
Data delayed at least 15 minutes, as of Nov 20 2019 17:34 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

  • Revenue in USD (TTM)3.62bn
  • Net income in USD583.76m
  • Incorporated1989
  • Employees2.50k
  • Location
    Vertex Pharmaceuticals Inc50 Northern AveBOSTON 02210-1862United StatesUSA
  • Phone+1 (617) 341-6393
  • Websitehttps://www.vrtx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VRTX:NSQ since
Semma Therapeutics IncAnnounced03 Sep 201903 Sep 2019Announced19.50%950.00m
Exonics Therapeutics IncDeal completed06 Jun 201906 Jun 2019Deal completed24.16%1.05bn
Data delayed at least 15 minutes, as of Nov 20 2019 17:34 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Iqvia Holdings Inc10.88bn236.00m27.72bn58.00k121.884.5219.042.551.171.2154.0531.600.4794--4.52187,603.501.212.151.442.6634.3732.042.523.61--1.990.64350.007.3215.35-27.97-0.229839.04--
Regeneron Pharmaceuticals Inc7.62bn2.09bn37.18bn7.40k18.923.6016.264.8818.2118.6966.4295.740.6160.74593.131,029,959.0016.8817.7419.3720.7592.2192.9127.4023.683.5125.230.06350.0014.2826.1055.8641.1419.63--
Vertex Pharmaceuticals Incorporated3.62bn583.76m55.29bn2.50k95.7810.5384.0015.272.248.2513.9220.420.59663.398.801,447,865.009.21-5.1111.49-6.6586.6088.1815.43-8.993.32402.490.0992--22.4620.25103.80--13.20--
Zoetis Inc6.15bn1.47bn57.31bn10.00k39.4121.4230.529.323.053.0312.745.620.5661.386.28615,000.0013.5710.6514.9812.7567.7466.0523.9716.423.029.620.706523.639.765.0128.5322.3712.9320.91
Allergan plc15.82bn-9.27bn60.80bn16.90k--1.04--3.84-27.89-27.8547.82178.220.15742.405.42935,952.70-9.21-3.61-10.01-3.8984.9783.23-58.53-28.240.8830.00420.278---0.961743.4124.17---3.81--
Celgene Corporation16.98bn5.80bn76.96bn8.85k13.496.3611.924.538.028.1323.5016.990.44941.307.561,918,437.0015.3510.8817.3512.1296.3195.9434.1624.472.806.520.62080.0017.5218.67-4.8922.5218.86--
Gilead Sciences, Inc.22.37bn2.71bn82.23bn11.00k30.883.9920.043.682.112.0917.4716.270.36235.376.602,033,182.004.3623.085.2028.2279.6084.3712.0443.522.876.070.542517.01-15.2414.59-46.0612.1737.10--
Data as of Nov 20 2019. Currency figures normalised to Vertex Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

51.03%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 201926.29m10.23%
Fidelity Management & Research Co.as of 30 Sep 201923.76m9.24%
The Vanguard Group, Inc.as of 30 Sep 201919.56m7.61%
BlackRock Fund Advisorsas of 30 Sep 201913.87m5.39%
SSgA Funds Management, Inc.as of 30 Sep 201911.31m4.40%
Capital Research & Management Co. (World Investors)as of 30 Sep 201910.59m4.12%
Wellington Management Co. LLPas of 30 Sep 20198.24m3.21%
Jennison Associates LLCas of 30 Sep 20195.98m2.33%
Renaissance Technologies LLCas of 30 Sep 20195.80m2.26%
AllianceBernstein LPas of 30 Sep 20195.78m2.25%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.